Exploratory Study of Mavacamten (MYK-461) in Patients with

Recruiting

18 years - 99 years

All

Phase 2

5 participants needed

1 Location

Brief description of study

The purpose of this study is to compare the effect of the investigational drug, mavacamten, (MYK-461), to a placebo (an inactive substance) in patients with Non-obstructive Hypertrophic Cardiomyopathy (nHCM).

Detailed description of study

This study is being done to test whether mavacamten is safe, and can be tolerated in nHCM and to study whether it helps to improve symptoms or ability to exercise.
Mavacamten is an investigational drug. This means that it has not been approved by the Food and Drug Administration (FDA) or any regulatory agency for routine clinical use, including the treatment of nHCM.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: cardiomyopathy,nHCM
Age: 18 years - 99 years
Gender: All

Updated on 19 Feb 2024. Study ID: 829315

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Exploratory Study of Mavacamten (MYK-461) in Patients with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction

Brief description of study

Detailed description of study

Eligibility of study

Find a site